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SHORT COMMUNICATION
A pilot study to evaluate the effects of Cl esterase inhibitor on the
toxicity of high-dose interleukin 2
A.C. Ogilvie', J.W. Baars', A.J.M. Eerenberg2, C.E. Hack2, H.M. Pinedol, L.G. Thijs3 &
J. Wagstaff
'Department ofMedical Oncology, Free University Hospital, Amsterdam, The Netherlands; 2Department ofAutoimmune Diseases,
Central Laboratory of the Netherlands Red Cross Blood Transfusion Services, Amsterdam, The Netherlands; 3Medical Intensive
Care Unit, Free University Hospital, Amsterdam, The Netherlands.
Summary In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose
(CD) 264 ± 26 x 106 IU m2] and Cl esterase inhibitor (C1-INH) (loading dose 2,000 U, followed by
500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard
(CD 66 ± 12 x 106 IU m-2) or escalating-dose (CD 99 ± 8 x 106 IU m-2) IL-2. IL-2-induced hypotension was
equivalent and complement activation was less after IL-2 + C1-INH (C3a = 10.5 ± 3.2 nmol -l1) than follow-
ing standard (14.1 ±8.4 nmoll') or escalating-dose (18.3 ± 2.9 nmnol' 1) IL-2. This study demonstrates that
Cl -INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to
ameliorate IL-2-induced toxicity.
Although interleukin 2 (IL-2) has proved to be an effective
therapy for some renal cell carcinoma and melanoma
patients, its utility has been limited by toxicity. Dose-limiting
toxicity consists of hypotension and damage to small blood
vessels, leading to a capillary leak syndrome characterised by
fluid retention and weight gain. The severity of the toxicity is
proportional to the IL-2 dose administered. During IL-2
therapy the complement system becomes activated (Thijs et
al., 1992; Moore et al., 1991; Vachino et al., 1991; Baars et
al., 1992; Clayman et al., 1992). This activation is dose
dependent (Thijs et al., 1990; Baars et al., 1992), occurs via
several pathways including the classical route (Thijs et al.,
1990; Moore et al., 1991; Vachino et al., 1991), and correlates
with the degree of hypotension induced (Baars et al., 1992)
and parameters of capillary leakage (Thijs et al., 1990; Baars
et al., 1992). The classical route of complement activation is
regulated by Cl esterase inhibitor (C1-INH). In a
preliminary study the administration of human C1-INH to
patients with septic shock appeared to be safe and was
probably associated with attenuation of complement activa-
tion (Hack et al., 1992). In this pilot study we have inves-
tigated the feasibility of using C1-INH to ameliorate the
hypotension induced by high-dose IL-2.
Patients and methods
Six patients (Table I) received a 1 h infusion of C1-INH
[2,000 units (U), Central Laboratory of The Netherlands Red
Cross Blood Transfusion Service, Amsterdam, The Nether-
lands] immediately prior to the first IL-2 infusion, and this
was repeated at a dose of 500 or 1,000 U every 12 h
thereafter for 4 days.
IL-2 (EuroCetus, Amsterdam, The Netherlands) was given
at a dose of 72 x 106 IU m-2 day-' for 4 days (the experi-
mental course). Three weeks after the experimental course
and following the resolution of all toxicity, the same patients
received a second cycle of IL-2 at a standard dose of
18 x 106 IU m2 day-' for 4 days but without C1-INH (self-
control course). Data from these patients were compared
with those from four other patients (Table I) who had
previously received IL-2 at escalating doses of
18-36 x 106 IU m-2 day-' also for 4 days (historical-control
course). All IL-2 was given by a 15 min infusion. The experi-
mental and historical-control courses were administered in
the intensive care department, and both groups received
parenteral nutrition. The self-control course was given in the
high-care section of the Oncology Department but without
parenteral nutrition.
Hypotension (systolic blood pressure >95 mmHg) was
treated initially with plasma expanders and where necessary
with dopamine or noradrenaline.
Blood samples for measurement of C1-INH and comple-
ment components were obtained and stored as previously
described (Nuijens et al., 1989). Total plasma C1-INH was
measured with a nephelometer (Behring Werke Nephelometer
Analyzer, Behring Werke) and expressed as a percentage of
normal by reference to pooled plasma from normal blood
donors (normal values 70-134%). Plasma C3a (levels
>5 nmol 1-1 are elevated) was measured with a competitive
radioimmunoassay (Hack et al., 1988).
Results were expressed as means and standard deviations.
Comparisons within and between groups were done by using
a paired Student t-test. Proportions were compared by using
Fisher's exact test. P-values <0.05 were considered statis-
Table I Patient characteristics
Cumulative IL-2 doses'
Age (years), Experimental Self-control
sex Diagnosis course course
Pilot study group
49, M Renal cell carcinoma 234 72
57, M Renal cell carcinoma 288 72
43, M Melanoma 288 72
46, F Renal cell carcinoma 288 36
55, M Melanoma 270 72
54, F Melanoma 216 72
Historical-control group
35, M Melanoma 108
57, M Renal cell carcinoma 90
51, M Melanoma 108
40, M Melanoma 90
M, male; F, female. ax 106IUm-2 over 4 days.
Correspondence: J. Wagstaff, Department of Medical Oncology,
Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam,
The Netherlands.
Received 10 September 1993; and in revised form 2 November
1993.
12" Macmillan Press Ltd., 1994 Br. J. Cancer (1994), 69, 596-598Cl ESTERASE INHIBITOR ADMINISTRATION DURING IL-2 THERAPY 597
C c
0
.0
E
0
4-
c
0 0
0
0
3
a
0
0
10
0
0
0
120
100
80
69
40
50
40
w-
E
C
co
30
20
10
0
0
0
0
0
0 50 100 150 200
Cumulative IL-2 (IU m-2)
250
Figure 1 Changes in mean blood pressure a, and in plasma C3a
levels b, during IL-2 therapy plotted against the cumulative dose
of IL-2 administered. The plotted values are those measured
immediately before IL-2 administration. Blood pressure is ex-
pressed as a percentage from baseline values. 0 O, experi-
mental course (IL-2 + Cl-INH); A ---A, self-control course;
O---0, historical-control course.
tically significant. Mean blood pressure was derived from the
sum of one-third systolic blood pressure and two-thirds dias-
tolic blood pressure. Changes in blood pressure between
groups were analysed by using the percentages of the baseline
values. The slope of linear trend in the measured variables
plotted against the cumulative dose of IL-2 administered was
determined with the linear regression technique.
Results
The cumulative IL-2 doses given during the experimental
course (264 ± 26 x 106 IU m-2) were significantly higher than
those during either the self- (66 ± 12 x 106 IUm2) or
historical- (99 ± 8 x 106 IU m-2) control courses.
Because the C1-INH plasma levels of the first patient did
not exceed 152% after 24 h, C1-INH was given in doses of
1,000 U every 12 h instead of 500 U thereafter.
The mean blood pressure decreased from 94± 8 to
77 ± 14 mmHg during the experimental course. This fall was
not significantly different from that seen during the self-
control course (98 ± 13 to 89 ± 10 mmHg) or the historical-
control course (89 ± 8 to 85 ± 8 mmHg). During the experi-
mental course the decrease in mean blood pressure plotted
against the administered IL-2 dose was less than that of the
self-control course (slope of linear trend -0.08 vs -0.15)
and similar to that observed during the historical-control
course (slope of linear trend -0.08) (Figure la). Vasopres-
sors were administered during an equivalent number of
patient days during the experimental and the historical-
a control courses (10/23 vs 6/10 respectively).
There was an equivalent gain in body weight during the
experimental and the historical-control courses, + 5 + 2.6%
vs + 3.6 ± 1.3%, both significantly greater than during the
self-control course (weight change -0.2 ± 1.7%). This
o difference was due to the greater fluid load from parenteral
nutrition rather than a more severe capillary leak syndrome
alone.
O°. Baseline plasma C3a values were in the normal range and
o did not differ significantly between courses. During the exper-
imental and self-control courses C3a rose to a similar degree
(10.5 ± 3.2 and 14.1 ± 8.4 nmol '-l at 96 h respectively) but
was significantly lower than after the historical-control course
(18.3 ± 2.9 nmol1'). The increase in plasma C3a levels plot-
ted against the administered IL-2 dose was less during the
experimental course (slope of linear trend 0.02) than during
b the self-control and historical-control courses (slope of linear
trend 0.12 and 0.14) (Figure Ib).
During the administration of C1-INH no side-effects were
observed. C1-INH administration caused a significant inc-
rease in the plasma levels of total C1-INH from 128 ± 28%
to 166 ± 39% immediately before the start of the IL-2
infusion in the experimental course. Total C1-INH increased
gradually thereafter to 195 ± 33% after 96 h. During the
self-control course total C1-INH did not change significantly
(148 ± 47 to 136 ± 19%). In the historical controls total Cl-
INH remained at baseline levels during the first two treat-
o ment days and thereafter it increased from 124 ± 16% to
o 178 ± 17% at 96 h after the start of IL-2.
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Discussion
These results demonstrate that in the patients who received
high doses of IL-2 (72 x 106 IUm2 day-') together with
C1-INH administration the degree of complement activation
was similar to that achieved when a subsequent course of
IL-2 was given at four times lower cumulative dose
(18 x 106 IU m-2day-') but without additional C1-INH (see
also Table I). Moreover, toxicity induced by the experimental
course of high-dose IL-2 and C1-INH administration was no
more severe than that observed in a historical-control group
which had received a 2.7 times lower cumulative dose of
IL-2. In addition, no toxic side-effects of C1-INH treatment
were observed.
Considering that IL-2 induces complement activation in a
dose-dependent manner, our observations are consistent with
the hypothesis that C1-INH administration can inhibit comp-
lement activation during IL-2 treatment and thus presumably
ameliorate IL-2-induced toxicity. C1-INH administered ac-
cording to this protocol was not associated with complete
inhibition of complement activation. The data may indicate
that optimalisation of the C1-INH dose and schedule, result-
ing in a 2-fold elevation of the C1-INH plasma level, might
result in a greater inhibition of complement activation and
thereby further reduce IL-2-related toxicity.
Modulation of early mediators of IL-2 toxicity, such as
tumour necrosis factor (TNF), can also result in reduced
toxicity (Mier et al., 1990). The dexamethasone used to
achieve suppression of TNF release was, however, associated
with undetectable NK activity in those patients and with the
lack of objective regressions in another study (Vetto et al.,
1987). Administration of C1-INH does not seem to interfere
with IL-2-induced NK and LAK cytotoxicity either in vitro
or in vivo in the experimental course (data not shown).
Furthermore the anti-tumour effects of IL-2 are not com-
pletely inhibited because one partial remission was observed
in the current study. Modulation of later mediators of tox-
icity such as complement may, therefore, be preferable.
The results from this open label pilot study warrant a
further double-blind randomised controlled trial of Cl-INH
administration during high-dose IL-2 immunotherapy.598 A.C. OGILVIE et al.
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